{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:47:23Z","timestamp":1794469643824,"version":"4.9.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,31]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>New data plus a literature review documented new thrombosis in only 1 (2.2%) of 46 patients with acute HIT who were treated with rivaroxaban. The literature review found similarly favorable results, albeit with fewer patients, when apixaban and dabigatran were used to treat acute HIT.<\/jats:p>","DOI":"10.1182\/blood-2017-04-778993","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T20:40:18Z","timestamp":1498250418000},"page":"1104-1113","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":187,"title":["Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-7588","authenticated-orcid":false,"given":"Theodore E.","family":"Warkentin","sequence":"first","affiliation":[{"name":"Department of Pathology and Molecular Medicine and"},{"name":"Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"McMaster Centre for Transfusion Research, Hamilton, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menaka","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine and"},{"name":"Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"McMaster Centre for Transfusion Research, Hamilton, ON, Canada; and"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori-Ann","family":"Linkins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111904180966200_B1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2011-11-376293","article-title":"How I treat heparin-induced thrombocytopenia","volume":"119","author":"Cuker","year":"2012","journal-title":"Blood"},{"key":"2019111904180966200_B2","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2011.1.143","article-title":"How I diagnose and manage HIT","author":"Warkentin","year":"2011"},{"key":"2019111904180966200_B3","author":"Linkins","year":"2012"},{"issue":"1","key":"2019111904180966200_B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2014.03.029","article-title":"Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study","volume":"134","author":"Schindewolf","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"2019111904180966200_B5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111904180966200_B6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.12592","article-title":"Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia","volume":"12","author":"Joseph","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111904180966200_B7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111904180966200_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2014.10.019","article-title":"Rivaroxaban for treatment of HIT: a riveting first experience","volume":"135","author":"Linkins","year":"2015","journal-title":"Thromb Res"},{"issue":"6","key":"2019111904180966200_B9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/1060028015579424","article-title":"Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia","volume":"49","author":"Miyares","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2019111904180966200_B10","author":"van Es","year":"2015"},{"issue":"2","key":"2019111904180966200_B11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11239-016-1365-0","article-title":"Novel oral anticoagulants for heparin-induced thrombocytopenia","volume":"42","author":"Skelley","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2019111904180966200_B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2008.07300.x","article-title":"Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia","volume":"143","author":"Walenga","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111904180966200_B13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/1076029613492876","article-title":"Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia","volume":"19","author":"Walenga","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"2019111904180966200_B14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-05-353391","article-title":"Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4\/heparin antibodies","volume":"119","author":"Krauel","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111904180966200_B15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11239-014-1064-7","article-title":"Design of the rivaroxaban for heparin-induced thrombocytopenia study","volume":"38","author":"Linkins","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"26","key":"2019111904180966200_B16","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2016-07-728030","article-title":"Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States","volume":"128","author":"Aljabri","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111904180966200_B17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/jth.13330","article-title":"Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study","volume":"14","author":"Linkins","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111904180966200_B18","first-page":"835","article-title":"Management of the multiple phases of heparin-induced thrombocytopenia","volume":"116","author":"Cuker","year":"2016","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019111904180966200_B19","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","article-title":"Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3","volume":"3","author":"Lubenow","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111904180966200_B20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"12","key":"2019111904180966200_B21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.21032","article-title":"What is the potential for overdiagnosis of heparin-induced thrombocytopenia?","volume":"82","author":"Lo","year":"2007","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111904180966200_B22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2141.1996.d01-1876.x","article-title":"The epitope specificity of heparin-induced thrombocytopenia","volume":"95","author":"Horsewood","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111904180966200_B23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.bloodjournal67127","article-title":"A diagnostic test for heparin-induced thrombocytopenia","volume":"67","author":"Sheridan","year":"1986","journal-title":"Blood"},{"issue":"12","key":"2019111904180966200_B24","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1111\/j.1538-7836.2011.04536.x","article-title":"Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis","volume":"9","author":"Warkentin","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111904180966200_B25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111904180966200_B26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.24006","article-title":"The platelet serotonin-release assay","volume":"90","author":"Warkentin","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111904180966200_B27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MOH.0000000000000273","article-title":"Management of heparin-induced thrombocytopenia","volume":"23","author":"Warkentin","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"2019111904180966200_B28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1503\/cmaj.131449","article-title":"Progressive thrombocytopenia after cardiac surgery in a 67-year-old man","volume":"186","author":"Kopolovic","year":"2014","journal-title":"CMAJ"},{"issue":"1","key":"2019111904180966200_B29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.thromres.2014.06.005","article-title":"First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Ng","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"2019111904180966200_B30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.thromres.2015.01.009","article-title":"New oral anticoagulants in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Sharifi","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"2019111904180966200_B31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MBC.0000000000000205","article-title":"Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia","volume":"26","author":"Hantson","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2019111904180966200_B32","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jtcvs.2015.04.054","article-title":"Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report","volume":"150","author":"Abouchakra","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2019111904180966200_B33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11239-015-1208-4","article-title":"Rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"40","author":"Sartori","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"2019111904180966200_B34","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216110","article-title":"Rivaroxaban in treatment refractory heparin-induced thrombocytopenia","author":"Casan","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"5","key":"2019111904180966200_B35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/FJC.0000000000000421","article-title":"Heparin-induced thrombocytopenia presenting with deep venous thrombosis and pulmonary embolism successfully treated with rivaroxaban: clinical case report and review of current experiences","volume":"68","author":"Samo\u0161","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"2019111904180966200_B36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00277-016-2871-z","article-title":"Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence","volume":"96","author":"Ong","year":"2017","journal-title":"Ann Hematol"},{"issue":"12","key":"2019111904180966200_B37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ccr3.411","article-title":"Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer","volume":"3","author":"Larsen","year":"2015","journal-title":"Clin Case Rep"},{"issue":"6","key":"2019111904180966200_B38","first-page":"798","article-title":"[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)] [in Spanish]","volume":"151","author":"Delgado-Garc\u00eda","year":"2015","journal-title":"Gac Med Mex"},{"issue":"3","key":"2019111904180966200_B39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11239-016-1458-9","article-title":"Acute apixaban treatment of heparin-induced thrombocytopenia","volume":"43","author":"Delgado-Garc\u00eda","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2019111904180966200_B40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11239-016-1420-x","article-title":"Direct oral anticoagulants in hypercoagulable states","volume":"43","author":"Kunk","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2019111904180966200_B41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4321\/S1137-66272012000300024","article-title":"[Dabigatran as a therapeutic possibility in heparin-induced thrombocytopenia type II]","volume":"35","author":"Anniccherico","year":"2012","journal-title":"An Sist Sanit Navar"},{"issue":"9","key":"2019111904180966200_B42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.mayocp.2013.06.013","article-title":"Dabigatran for heparin-induced thrombocytopenia","volume":"88","author":"Anniccherico","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2019111904180966200_B43","first-page":"112","article-title":"Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia","volume":"9","author":"Mirdamadi","year":"2013","journal-title":"ARYA Atheroscler"},{"issue":"3","key":"2019111904180966200_B44","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH14-07-0593","article-title":"Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban","volume":"114","author":"Tardy-Poncet","year":"2015","journal-title":"Thromb Haemost"},{"key":"2019111904180966200_B45","first-page":"985253","article-title":"Heparin-induced thrombocytopenia in a patient with essential thrombocythemia: a case based update","volume":"2015","author":"Noel","year":"2015","journal-title":"Case Rep Hematol"},{"issue":"1","key":"2019111904180966200_B46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5152\/eurasianjmed.2015.95","article-title":"Massive pulmonary embolism in a patient with heparin induced thrombocytopenia: successful treatment with dabigatran","volume":"48","author":"Bircan","year":"2016","journal-title":"Eurasian J Med"},{"issue":"7","key":"2019111904180966200_B47","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ajh.23971","article-title":"Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment","volume":"90","author":"Tvito","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111904180966200_B48","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1345\/aph.1Q474","article-title":"Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies","volume":"46","author":"Fieland","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2019111904180966200_B49","first-page":"15","article-title":"Dabigatran as alternative anticoagulant for intra-aortic balloon pump in a patient with suspected heparin-induced thrombocytopenia","volume":"21","author":"Lee","year":"2013","journal-title":"J Hong Kong Coll Cardiol"},{"issue":"3","key":"2019111904180966200_B50","first-page":"47","article-title":"Dabigatran in heparin induced thrombocytopenia; report of two cases","volume":"15","author":"Eshraghi","year":"2014","journal-title":"Iranian Heart J."},{"key":"2019111904180966200_B51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40278-015-9206-z","volume":"1545","author":"Heparin-induced thrombocytopenia: 2 case reports","year":"2015","journal-title":"Reactions Weekly"},{"issue":"5","key":"2019111904180966200_B52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.thromres.2005.04.011","article-title":"Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and\/or coumarin explain the rapid shift in clinical practice during the 1990s","volume":"117","author":"Lubenow","year":"2006","journal-title":"Thromb Res"},{"issue":"6","key":"2019111904180966200_B53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1160\/TH05-07-0489","article-title":"Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004","volume":"95","author":"Magnani","year":"2006","journal-title":"Thromb Haemost"},{"key":"2019111904180966200_B54","author":"Warkentin","year":"2008"},{"issue":"14","key":"2019111904180966200_B55","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"2019111904180966200_B56","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"issue":"1","key":"2019111904180966200_B57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/14740338.2013.823946","article-title":"Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls","volume":"13","author":"Warkentin","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2019111904180966200_B58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.jvca.2014.04.029","article-title":"Progressive, fatal thrombosis associated with heparin-induced thrombocytopenia after cardiac surgery despite \u201ctherapeutic\u201d anticoagulation with argatroban: potential role for PTT and ACT confounding","volume":"29","author":"Smythe","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/9\/1104\/1405076\/blood778993.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/9\/1104\/1405076\/blood778993.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:19:38Z","timestamp":1574137178000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/9\/1104\/36991\/Direct-oral-anticoagulants-for-treatment-of-HIT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,8,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-04-778993","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727749780.793541206","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.727749780.793541351","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}